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A B S T R A C T
Resistant hypertension represents a major health problem despite the plethora of an-
tihypertensive drugs. Activation of the sympathetic nervous system is considered to 
be the basis of its pathogenesis. Two novel invasive therapeutic strategies for the treat-
ment of resistant hypertension have recently emerged, namely catheter based renal 
sympathetic denervation and carotid baroreceptor stimulation. Both are effective in 
reducing elevated blood pressure values and display a good tolerability profile without 
the occurrence of any major untoward effect.
I N T R O D U C T I O N
Hypertension (HTN) has a prevalence of 26.4% in the age group 30-60, rising to 
65% in those over 60 years of age 1 affecting nearly 72 million people in the USA, and 
1 billion worldwide. It is a major risk factor for cardiovascular disease, stroke, heart 
failure, and premature renal failure, and a major cause of morbidity and mortality, 
responsible for 7 million deaths annually.2 Yearly costs to treat hypertension in the 
United States are estimated to be $69.4 billion; nevertheless only 25-35% of hyper-
tensive patients achieve a blood pressure <140/90 mmHg.
Hypertension is defined as resistant or refractory to treatment when a therapeutic 
plan that has given attention to lifestyle measures and the prescription of at least three 
drugs (including a diuretic) at their maximum or highest tolerated doses has failed to 
lower systolic and diastolic blood pressure <140/90 mmHg in general (130-139/80-85 
mmHg in patients with diabetes mellitus and <130/80 mmHg in chronic renal disease).3 
P R E V A L E N C E  A N D  H E A L T H  B U R D E N
Resistant hypertension has a reported prevalence as high as 13%-18% in men and 
22% among women (AHA 2010).4 The high prevalence of hypertension in the general 
population renders this small percentage significant in terms of actual patient numbers. 
The most common causes of resistant hypertension is poor compliance or limitations 
in drug therapy (inadequate dosing, polypharmacy, adverse drug effects) or non-ad-
herence to recommended lifestyle changes (particularly elimination of alcohol abuse). 
Other not infrequent causes of resistant hypertension are obstructive sleep apnea, 
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renal artery stenosis, volume overload due to progressive renal 
insufficiency, hyperaldosteronism, excessive salt intake, and 
most often, insufficient diuretic therapy. Rare causes include 
pheochromocytoma, Cushing syndrome, hyperparathyroid-
ism, and coarctation of the aorta. Finally pseudohypertension 
must be excluded.4,5 All these forms of HTN have a significant 
neurogenic component which is initiated and sustained in part 
by activation of the sympathetic, and inhibition of the para-
sympathetic, system, resulting in vasoconstriction, increased 
cardiac output, renin secretion, reduction in renal blood flow 
and sodium and water retention (Fig. 1).
In the 50’s, non selective surgical sympathectomy was 
the last option for malignant hypertension but it was driven 
to total obscurity due to serious adverse effects, despite its 
efficacy in reducing blood pressure and a long-term duration 
of the results and also due to the development of new antihy-
pertensive drugs.10,11 Recently, other approaches have been 
used to decrease sympathetic outflow, the electrical activation 
of the carotid baroreceptors using an implantable device (the 
Rheos System, CVRx Inc., Minneapolis, Minnesota) and the 
selective renal sympathetic denervation (RSD) carried out by 
endovascular, catheter-based, radiofrequency ablation (RFA) 
of the renal afferent nerves.
(baroreceptors) located in the adventitia of the large systemic 
arteries, mainly the aortic arch and carotid sinuses. They encode 
mean arterial pressure (P) and its derivative (dp/dt) in action 
potentials that are transmitted along sensory fibers to the 
nucleus tractus solitarius (NTS) and sensory nucleus of the IXth 
(i.e. glossopharyngeal) and Xth (i.e. vagus) cranial nerves. The 
final result is inhibition of the sympathetic cardiovascular drive 
and stimulation of the vagal influences on the heart (negative 
feedback). However, baroreceptor response adapts over min-
utes to days, and a new threshold for activation is established 
(baroreceptors become less sensitive to any given change in 
blood pressure) as in the case of chronic hypertension, where 
this homeostatic function is impaired leading to vasoconstriction 
and tachycardia (Fig. 2)- an effect attributed to altered activity 
in the brain portion of the reflex.6-8 Recent evidence, however, 
calls into question the notion that the baroreflex is blunted in 
long-term BP control 9 and therefore prolonged activation of 
the baroreflex produces sustained hypotension.12
Preliminary studies in experimental animals, conducted 
to restore the baroreceptor function, showed that carotid 
sinus stimulation (interpreted by the brain as a rise in BP) 
is able to lower blood pressure and reduce circulating levels 
of norepinephrine.13 Voltage-response curves are consistent, 
apparent and high linear (Fig. 3).14, 15
D E V I C E  A N D  T E C H N I Q U E
The Rheos CVRx Baroreflex Hypertension Therapy Sys-
tem resembles a pacemaker; it has three components: 1) The 
Rheos pulse generator (PG). This consists of a battery and a 
FIGURE 1. Pathophysiology of resistant hypertension (Papad-
emetriou V, Int J Hypertens 2011).10
C A R O T I D  S I N U S  S T I M U L A T I O N 
Neural control of the circulation is regulated by numerous 
hormonal and neural reflexes. The most important of these are 
the arterial baroreflexes which first respond to arterial pressure 
changes, regulate heart rate, cardiac contractility and vasomotor 
tone and participate in short and long term control of blood 
pressure (BP). The baroreflex is initiated by stretch receptors FIGURE 2. Aortic and carotid receptors.
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circuit system which delivers 1 to 7.5 V of activation energy; 
2) Two bilateral carotid sinus leads that are connected to the 
pulse generator via flexible wires and to the carotid sinus by 
an electrode with an insulative backer and; 3) The Rheos 
Programmer System that allows control of the generator via 
radiofrequency coup (Fig. 4).13 The device is surgically im-
planted. The operation can be divided into three phases: phase 
1, induction of anesthesia and exposure of the carotid bifurca-
tions; phase 2, carotid sinus mapping, electrode fixation, and 
testing; and phase 3, tunneling and wound closure. In general, 
inhalation anesthetics should be minimized or avoided during 
the first two phases, to preserve the reflex but conventional 
anesthesia can be used during phase 3. The PG is implanted 
in a pocket created infraclavicularly usually on the right side 
(to avoid confusion with the typical left-sided pacemaker or 
implantable defibrillator placement).17 
Recently, a second-generation implantable device, the 
Barostim neo™ CVRx received CE mark approval for hyper-
FIGURE 4. Position of the carotid sinus leads and impulse gen-
erator.
FIGURE 5. The Barostim neo CVRx system (Courtesy of CVRx.
com).
tension. It features a new unilateral, 1mm electrode and a new 
smaller, more advanced stimulator to allow for more focused 
and efficient delivery of therapy. These improvements have 
led to shorter procedure times and extended longevity (Fig. 
5). The Barostim neo is CE marked and approved for sale for 
hypertension patients in Europe.
S T U D I E S
The European DEBuT-HT (Device Baced Therapy in Hy-
pertension) study, and the US Rheos FeasibilityTrial 2010),18 
were two small, prospective, multicenter, nonrandomized, 
phase II, single-arm, open-label, feasibility studies, to assess 
whether Rheos System therapy could safely lower BP. A total 
of 45 patients with BP ≥160/90 mmHg, despite at least three 
antihypertensive drugs, were enrolled and followed up for as 
long as 2 years. Mean BP was reduced by 21/12 mmHg after 3 
months of device therapy and by 33/22 mmHg (p=0.001, 0.002) 
in 17 pts after 2 years of follow up. In addition heart function 
was improved, left ventricular hypertrophy (LVH) significantly 
regressed and kidney function was preserved after one year of 
follow up.19 However, 19% (8 of 42 implantations) were fol-
lowed by severe complications (e.g., stroke, glossoplegia, device 
displacement or infection [5.5%]). Two generators had to be 
changed for planned battery replacement in patients requiring 
high voltages for blood pressure control.20 Four-year results of 
the DEBuT-HT Investigators (2011)24 showed mean BP reduc-
tion by 53 /30 mmHg (p-value <0.001, p-value = 0.002) and 
pulse rate reduction by -5 ± 14 bpm ± SD (p-value = 0.03).
The recently published Rheos Pivotal Trial (2011)25 is a 
double- blind, randomized, prospective, multicenter, placebo-
controlled, phase III clinical trial, in the US, to assess the safety 
and efficacy of the baroreflex activation therapy (BAT) delivered 
through the Rheos System in 265 pts with resistant HTN. The 
main enrollment criterion was resistant HTN (defined as at least 
one, out-patient, in-office BP ≥160/80 mmHg), with additional 
enrollment criteria ambulatory SBP ≥135 mm Hg for 24 hours 
in the absence of clinical significant orthostatic BP changes. 
Patients were implanted and randomized (2:1) one month after 
implantation. Subjects received either BAT for the first 6 months 
FIGURE 3. Blood pressure and heart rate reduction using ba-
roreflex activation therapy from 1 to 3 volts. Note that acutely 
blood pressure was reduced from 210/96 to 144/66 and heart rate 
from 71 to 50 beats per minute (Courtesy of CVRX.com).
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(Group A) or delayed BAT initiation after this period (Group 
B). The five co-primary endpoints were two for efficacy and three 
for safety, as follows: 1) acute systolic BP efficacy at 6 months, 
2) sustained efficacy at 12 months, 3) procedure safety, 4) BAT 
safety and 5) device safety. The trial showed significant benefit 
for the endpoints of sustained efficacy (88% responders), BAT 
safety (Group A 91.7%, Group B 89.3%; p<0.001) and device 
safety (event-free rate 87.2%; p<0.001). However, it did not 
meet the endpoints for acute efficacy (at 6 months Group A 54% 
responders, Group B 46%; p=ns) or procedural safety (event-
free rate 74.8% which is less than the pre-specified objective 
performance criterion of 82%; p=1.00). A protocol-specified 
ancillary analysis showed 42% (Group A) versus 24% (Group B) 
achieving systolic BP ≤140 mmHg (p=0.005) with both groups 
achieving over 50% at 12 months, at which point Group B had 
received 6 months of BAT. 
The adverse events were procedure-related: transient 
(4.4%) or permanent (4.8%) nerve injury at the time of im-
plant, general surgical complication, respiratory complaint or a 
wound complication (2.6%); BAT-related: hypertensive crisis 
(Group A 5%; Group B 8.3%); device-related: hypertension-
related stroke (2.3%). The authors explained that nerve injury 
was the main contributor to the adverse events, and that per-
forming a unilateral implant may reduce the complexity and 
duration of the procedure.
Recently, Barostim neo CVRx , the new technology for 
delivering BAT system, showed systolic BP reductions by 28.7 
mmHg, in 12 resistant hypertension patients, 3 months after 
activation, comparable to the results of the Rheos System 
(systolic BP reduction -29.1 mmHg) (Husenfuss, European 
Society of Hypertension, 2011).
In conclusion, BAT seems to ach ieve effective lasting 
reduction of blood pressure with relative safety. However, 
its clinical application is limited by the necessity of vascular 
surgery of the carotid artery, under general anesthesia, the 
need for frequent replacement of the device and the risk of 
infection entailed by device implantation. Future clinical tri-
als will address the limitations of this study and further define 
the therapeutic benefit of the method. Today it represents a 
specific treatment in selected patients with severe resistant 
hypertension.5 The Barostim neo is CE marked and approved 
for sale for hypertension patients in Europe.
R E N A L  S Y M P A T H E T I C  D E N E R V A T I O N 
( R S D )
The autonomic control of the kidney is predominantly 
sympathetic. Renal nerves run alongside the renal artery and 
enter the hilus of the kidney. Thereafter, they divide following 
the blood vessels, and penetrate the cortical and juxtamadul-
lary areas (Fig. 6).
Efferent renal sympathetic nerve activation, when weak, 
enhances noradrenaline production or spillover and renin secre-
tion from the granular juxtaglomerular cells, via beta1 adrener-
gic receptors. Stronger sympathetic nerve stimulation, via alpha1 
adrenergic receptors, enhances sodium reabsorption from the 
tubules and renal vasoconstriction, resulting in renal blood flow 
reduction. Afferent renal sympathetic nerves originate mostly 
from the renal pelvic wall (with mechanoreceptors responding 
to stretch and chemoreceptors detecting renal ischemia) whose 
cell bodies lie in the ipsilateral dorsal root ganglia (T6-L4). From 
there ascending signals travel to the renal cardiovascular centers 
in the central nervous system, mainly in the hypothalamic area, 
and promote vasopressin and oxytocin release from the neuro-
hypophysis. Overall, afferent sympathetic fibers have important 
contribution in regulation of systemic vascular resistance and 
BP control. Complete renal denervation effectively inhibits 
ascending afferent stimuli without functional regeneration or 
reinnervation contributing in the BP therapy.3,30,35
H I S T O R I C A L  P E R S P E C T I V E  O F  S Y M PA T H E T I C 
D E N E R VA T I O N
Non-selective surgical sympathectomy has been applied 
mainly in patients with severe or malignant hypertension as 
well as in patients with cardiovascular deterioration despite 
relatively good blood pressure reduction by other means. After 
the introduction of antihypertensive drugs, sympathectomy was 
reserved for patients who failed to respond to antihypertensive 
therapy or could not tolerate it. Total sympathectomy (from 
8th to 12th dorsal vertebra) is impractical and poorly tolerated 
by humans. It was performed only in a few selected centers, 
in either 1 or 2 stages, and required a prolonged hospital stay 
(2 to 4 weeks). Adverse events were common and included 
postural hypotension and tachycardia, palpitation, breath-
lessness, anhydrosis, cold hands, intestinal, bowel and sexual 
dysfunction, thoracic duct injuries and atelectasies. However, 
FIGURE 6. Sympathetic innervation of the kidney (Papademe-
triou V, Int J Hypertens 2011).
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sympathectomy was associated with higher survival rates, more 
than doubled, in patients who underwent the procedure (Fig. 
7).26 Percutaneous renal sympathectomy (RSD) has several 
advantages over the radical sympathectomy; it is localized, 
minimally invasive, without systematic side effects and with 
short procedural and recovery times.
T E C H N I Q U E
Renal artery angiography is performed to assess anatomic 
eligibility for the procedure and to confirm the absence of sig-
nificant renal artery stenosis. A flexible ablation catheter (Sym-
plicity TM Catheter System, Ardian/Medtronic Inc., California, 
USA) is then introduced percutaneously via the femoral artery 
and advanced to the distal segment of the renal artery. The 
proximal end of the catheter is connected to a radiofrequency 
(RF) generator to apply a discrete RF ablation lasting 2 minutes. 
Up to six ablations are performed in each artery, separated both 
longitudinally (of at least 5 mm) and rotationally to achieve 
circumferential coverage of the renal artery. Catheter tip tem-
perature (50-70 oC) and impedance are constantly monitored 
during ablation and RF energy delivery (maximum 8 Watts) is 
regulated according to a predetermined algorithm (Fig. 8).27 The 
heating of the wall ablates the sympathetic nerve fibers in the 
adventitia. Bilateral percutaneous RSD can be accomplished 
in 40-60 minutes. The ablation procedure is accompanied by 
diffuse visceral non-radiating abdominal pain which does not 
persist beyond the RF energy application and can be managed 
by intravenous narcotics and sedatives. 
R E C E N T  S T U D I E S 
Renal sympathetic denervation (RSD) is evaluated in the 
multicenter proof –of –concept Simplicity HTN -1 study and 
the randomized controlled Simplicity HTN-2.trial. In the Sym-
plicity HTN-1 Study, 28 50 patients with resistant hypertension 
were studied and resulted in impressive blood pressure reduc-
tions. After only one month systolic and diastolic BP decreased 
significantly by 14/10 mm Hg respectively and after a 12-month 
follow up period by 27/17 mm Hg (Fig. 9) without subsequent 
increase in BP in the original study period or in the recently 
published follow up (153 patients) of a period of 24 months.29 
The reduction in BP at 6 months after RSD was accompa-
nied by a significant decrease (-47%) in the renal norepineph-
rine spillover rate. Only two adverse events occurred, one renal 
artery dissection and one femoral artery pseudoaneurysm.28 
This study demonstrated, for the first time in humans, that 
RSD can reduce blood pressure in a safe way with long acting 
results. However, the study created several concerns and many 
questions. It lacked a proper control group (not randomized), 
it was small, the group of patients recruited was not clearly 
defined, predictors of blood pressure response had not been 
FIGURE 7. Long-term blood pressure control following surgical sympathectomy (Papademetriou V, Int J Hypertens 2011).
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identified, the potential for tissue damage (that will result in 
structural changes of the renal artery) was not defined.30,31 
Recently, a second catheter-based RSD study, the multi-
center, prospective, randomized Symplicity HTN-2 Trial32 was 
published confirming the initial results in a controlled sample. 
A total of 106 patients with resistant hypertension (systolic BP 
≥160 mmHg; for patients with diabetes mellitus type 2 ≥150 
mmHg) were enrolled between June 2009 and January 2010. 
The primary effectiveness end point was the between-group 
change in average office-based measurements in systolic BP 
from baseline to 6 months post randomization. Secondary 
end points included a) acute and chronic procedural safety 
(reduction of eGFR >25% or new stenosis>60% confirmed 
by angiography at 6 months), b) a composite cardiovascular 
endpoint (myocardial infarction, sudden cardiac death, etc) 
and additional BP reduction at 6 months after randomization 
(systolic BP - 10 mmHg or more, achievement of target systolic 
BP, and change in home-based BP measurements). An initial 
2-week observation period was followed by randomization 
1:1 into a treatment group (52 patients) and a control group 
(continuation of drug treatment) (54 patients). Six months 
after renal denervation, mean BP in the treatment group had 
decreased significantly by 32/12 mmHg (Fig. 10) (p<0.0001), 
while the BP in the control group remained unchanged. Home 
BP also decreased by 20/12 mmHg (p<0.0001, n=32) in the 
RSD group compared with a slight increase of 2/0 mmHg 
(n=40) in the control group. In 20% of patients the reduc-
tion in BP permitted a decrease in the number or dosage of 
antihypertensive medications. Blood pressure control (defined 
as systolic BP<140 mmHg) was achieved in 39% of patients 
in the RSD group and in 3% in the control group.
However, it is also important to note that there is a sub-
stantial variability with regards to the BP effects, and that the 
procedure fails to reduce BP in about 10% of treated patients. 
A total of 84% of RSD patients had a reduction of systolic 
BP>10 mmHg. The reduction of BP is observed at rest and 
during exercise, with preservation of BP adaptation, and no 
signs of chronotropic incompetence or a negative influence 
on ventilator parameters. The glucose metabolism is favorably 
influenced by RSD with reductions in glucose and insulin con-
FIGURE 8. Percutaneous catheter-based renal sympathetic den-
ervation (schematic representation)
FIGURE 9. Blood pressure results from Symplicity HTN-1 
Study. DBP = diastolic blood pressure; SBP = systolic blood 
pressure.
FIGURE 10. Six months after renal denervation mean blood 
pressure in the treatment group had decreased significantly by 
32/12 mm Hg; DBP = diastolic blood pressure; SBP = systolic 
blood pressure.
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centration and improvement in insulin sensitivity as is shown 
in another study of 50 patients. 33 
S A F E T Y  A N D  C O N T R A I N D I C A T I O N S 
The procedure was without immediate serious complica-
tions in 201 (98%) of the 206 patients. Minor periprocedural 
events included 1 pseudoaneurysm of the femoral artery treat-
ed conservatively. In one patient the procedure led to renal 
artery dissection, unconnected with RF ablation and treated 
with a stent. Another patient showed worsening of a pre-
existing renal artery stenosis after 6 months, also managed by 
stenting. Other minor complications after renal denervation, 
each found in one patient, comprised short-term back pain 
(necessitating the administration of analgesic and sedatives 
which ceased immediately on termination of the ablation), 
a post-procedural decrease in blood pressure, urinary tract 
infection, and prolongation of hospital stay due to paresthesias. 
Seven patients presented with transient bradycardia during the 
procedure, and were treated with atropine. In two patients 
RSD was followed by a decrease in eGFR>25%. During 
follow-up, serious adverse events occurred in 4 denervation 
patients (1 with nausea and edema possibly related to under-
lying hypertension, 1 with a hypertensive crisis after abruptly 
stopping clonidine, 1 transient ischemic attack, and 1 patient 
who received a coronary stent for angina) and 2 controls (1 
transient ischemic attack, 1 coronary stent for angina). Con-
traindications for RSD include unfavorable anatomy of the 
renal artery (diameter <4 mm; length <20 mm), fibromuscular 
dysplasia, significant renal artery stenosis, other abnormalities 
of the renal arteries, and GFR<45 ml/min/1.73 mm2.28,34 
C O N C E R N S
Concerns with the present study include the relatively 
small sample size and short duration of follow up, use of only 
a handful of experienced operators, and a study design that did 
not require the placebo group to undergo a sham procedure, 
which would have made the study double blind. Addition-
ally, patients with secondary and white coat HTN were not 
excluded. The extent of ablation induced on afferent RSD 
is not currently known and the cost effectiveness needs to be 
carefully examined (the cost is high, around $12.000). 
In conclusion, the procedure is not technically difficult, 
appears to be safe, takes about 40 minutes to perform, and 
only requires periprocedural analgesia. Its long-term efficacy 
and cost-effectiveness remain to be determined. 
T H E  F U T U R E  O F  R E N A L  S Y M PA T H E T I C 
D E N E R VA T I O N
Renal sympathetic denervation (RSD) should be con-
ducted in more patients, with more operators, and longer fol-
low up (>2 years) in different registries necessary to evaluate 
the long term effects and the safety of the procedure. Also 
RSD should be conducted in other conditions, such as older 
age, obesity, diabetes, sleep apnea, essential hypertension, 
left ventricular hypertrophy (LVH), congestive heart failure, 
chronic or end-stage kidney disease, conditions characterized 
by hyperactive sympathetic nervous system drive. At present 
time, although attractive, RSD is difficult to be accepted at the 
early stages or in milder forms of hypertension. Current rec-
ommendations suggest that it should be reserved for patients 
in whom drug therapy fails. However, in the future, RSD can 
possibly be used as initial therapy in younger patients obtain-
ing greater benefit. Although not yet approved by the FDA 
for commercial distribution in the US, the system has been 
commercially available in Australia and Europe since April 
2010. According to the company, the Symplicity system has 
been used since 2007 to treat more than 2,000 patients with 
treatment-resistant hypertension worldwide. In August 2011, 
the FDA granted Medtronic approval to conduct SYMPLIC-
ITY-HTN-3, a US clinical trial of the system in patients with 
treatment-resistant hypertension. SYMPLICITY HTN-3 is a 
single-blind, randomized controlled trial designed to evalu-
ate the safety and effectiveness of renal denervation with the 
company’s Symplicity catheter system in patients with resistant 
hypertension. The study will enroll approximately 500 patients 
at 60 medical centers in the United States. The patients will 
be randomized to receive either renal denervation and treat-
ment with antihypertensive medications or treatment with 
antihypertensive medications alone. The primary endpoints 
of the study are the change in blood pressure from baseline to 
6 months after randomization and incidence of major adverse 
events at 1 month after randomization. Another objective is to 
better identify specific or ethnic populations who will respond 
best to this procedure.
Another study, the SYMPLICITY-HF clinical trial, will 
examine whether regulating sympathetic activity through 
renal denervation may also provide benefit in patients with 
both heart failure and renal insufficiency, two other conditions 
characterized by hyperactive sympathetic nervous system drive. 
The multicenter, prospective, open-label Global SYMPLIC-
ITY Patient Registry will evaluate the long-term impact of 
renal denervation in more than 5,000 patients. The registry 
will facilitate the collection of real-world data on the safety, 
efficacy and outcomes of the Symplicity renal denervation 
system in patients with a number of conditions associated 
with hyperactive sympathetic nervous system drive, including 
treatment-resistant hypertension, heart failure, insulin resis-
tance, chronic kidney disease and sleep apnea. To this end, 
the German Renal Denervation (GREAT) registry has been 
established to enable systematic follow-up of patients treated 
with renal denervation.
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